BlackRock
MNPR icon

BlackRock’s Monopar Therapeutics MNPR Stock Holding History

BlackRock’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.3M Buy
348,819
+32,252
+10% +$2M ﹤0.01% 2949
2026
Q1 		$17.3M Buy
316,567
+61,710
+24% +$3.73M ﹤0.01% 3169
2025
Q4 		$16.6M Buy
254,857
+51,106
+25% +$4.18M ﹤0.01% 3183
2025
Q3 		$16.6M Sell
203,751
-1,418
-0.7% -$63.4K ﹤0.01% 3196
2025
Q2 		$7.34M Buy
205,169
+190,705
+1,318% +$6.93M ﹤0.01% 3570
2025
Q1 		$527K Buy
14,464
+6,363
+79% +$229K ﹤0.01% 4380
2024
Q4 		$178K Buy
+8,101
New +$136K ﹤0.01% 4646
2022
Q3 		– Sell
-465
Closed -$5K – 5881
2022
Q2 		$5K Sell
465
-2,278
-83% -$25.8K ﹤0.01% 5682
2022
Q1 		$35K Sell
2,743
-112
-4% -$1.66K ﹤0.01% 5482
2021
Q4 		$46K Buy
2,855
+62
+2% +$1.38K ﹤0.01% 5417
2021
Q3 		$68K Sell
2,793
-216
-7% -$5.59K ﹤0.01% 5235
2021
Q2 		$89K Buy
3,009
+763
+34% +$21.8K ﹤0.01% 5082
2021
Q1 		$70K Buy
2,246
+1,168
+108% +$42.6K ﹤0.01% 4880
2020
Q4 		$33K Buy
1,078
+537
+99% +$13.9K ﹤0.01% 4722
2020
Q3 		$14K Sell
541
-185
-25% -$5.98K ﹤0.01% 4763
2020
Q2 		$27K Buy
726
+165
+29% +$6.34K ﹤0.01% 4654
2020
Q1 		$20K Buy
+561
New +$35.1K ﹤0.01% 4622

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

BlackRock's MNPR Position: Q2 2026 in Review

BlackRock increased its Monopar Therapeutics (MNPR) stake by 10% in Q2 2026, buying an estimated $2M and bringing the position to 348,819 shares worth $32.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2949.

BlackRock first reported a position in MNPR in Q1 2020 and has held it in 17 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • BlackRock held 348,819 shares of Monopar Therapeutics worth $32.3M as of Q2 2026.
  • BlackRock bought 32,252 Monopar Therapeutics shares in Q2 2026, an estimated $2M.
  • Monopar Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2949 holding.
  • BlackRock first reported a position in Monopar Therapeutics in Q1 2020 and has held it in 17 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.